Preclinical activity and safety of MGD006, a CD123xCD3 Bispecific DART® molecule for the treatment of hematological malignancies

被引：3
|
作者：
Moore, P. [1 ]
Chichili, G. R. [1 ]
Huang, L. [1 ]
Li, H. [1 ]
Burke, S. [1 ]
Chen, F. [2 ]
He, L. [1 ]
Tang, Q. [1 ]
Jin, L. [1 ]
Gorlatov, S. [1 ]
Ciccarone, V. [1 ]
Koenig, S. [1 ]
Shannon, M. [1 ]
Alderson, R. [1 ]
Johnson, S. [1 ]
Bonvini, E. [1 ]
机构：
[1] MacroGenics, Rockville, MD USA
[2] MacroGenics, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70264-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138
引用
收藏
页码：48 / 48
页数：1
相关论文
共 50 条
  • [21] Novel CD123xCD3 Bispecific Igm Antibody, Igm-2537, Potently Induces T-Cell Mediated Cytotoxicity of Acute Myeloid Leukemia Cells In Vivo and in Vitro with Minimal Cytokine Release
    Li, Gene
    Ye, Zhongde
    Yakkundi, Poonam
    Manlusoc, Marigold
    Logronio, Kathryn
    Tahrani, Leyla
    Rosete, Rodnie
    Bernados, David
    Hinton, Paul
    Pandya, Deepal
    Hanna, Nardeen
    Anantam, Jey
    Kotturi, Maya F.
    Bogaert, Liz
    Hong, Jiyoung
    Tsai, Christina
    Manley, Thomas
    Keyt, Bruce A.
    Sinclair, Angus M.
    Liu, Liqin
    BLOOD, 2023, 142
  • [22] Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
    Jacobs, Kenneth
    Viero, Cedric
    Godwin, John
    Baughman, Jan
    Sun, Jichao
    Ying, Kang
    Muth, John
    Hong, Shengyan
    Vey, Norbert
    Sweet, Kendra L.
    Uy, Geoffrey L.
    Ravandi, Farhad
    Foster, Matthew C.
    Rizzieri, David A.
    Arellano, Martha L.
    Rettig, Michael P.
    Topp, Max S.
    Huls, Gerwin
    Lelievre, Helene
    Paolini, Stefania
    Ciceri, Fabio
    Carrabba, Matteo Giovanni
    Lowenberg, Bob
    DiPersio, John F.
    Wigginton, Jon
    Davidson-Moncada, Jan K.
    BLOOD, 2018, 132
  • [23] In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014
    Nordstrom, J. L.
    Gay, C. L.
    Bohac, C.
    Wahl, A. R.
    Morgan, T.
    Schmitz, J. L.
    Li, H.
    Cotshott, J.
    Gobburu, J.
    Macintyre, A. N.
    Gorelick, R. J.
    Ferrari, G.
    Margolis, D. M.
    Garcia, J. V.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 6 - 7
  • [24] Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 X CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Rutella, Sergio
    Church, Sarah E.
    Vadakekolathu, Jayakumar
    Viboch, Elena
    Sullivan, Amy H.
    Hood, Tressa
    Warren, Sarah E.
    Cesano, Alessandra
    La Motte-Mohs, Ross
    Muth, John
    Lelievre, Helene
    Lowenberg, Bob
    DiPersio, John F.
    Davidson-Moncada, Jan K.
    BLOOD, 2018, 132
  • [25] SAFETY, TOLERABILITY, AND FUNCTIONAL ACTIVITY OF MGD010, A DART® MOLECULE TARGETING CD32B AND CD79B, FOLLOWING A SINGLE DOSE ADMINISTRATION IN HEALTHY VOLUNTEERS
    Pandya, N.
    Chen, W.
    Lohr, J.
    Yao, X. -T.
    Burns, R.
    Li, H.
    Li, H.
    Muth, J.
    Goldwater, R.
    Bonvini, E.
    Johnson, S.
    Moore, P.
    Wigginton, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 132 - 133
  • [26] Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
    Panowski, Siler H.
    Kuo, Tracy C.
    Zhang, Yi
    Chen, Amy
    Geng, Tao
    Aschenbrenner, Laura
    Kamperschroer, Cris
    Pascua, Edward
    Chen, Wei
    Delaria, Kathy
    Farias, Santiago
    Bateman, Marjorie
    Dushin, Russell G.
    Chin, Sherman M.
    Van Blarcom, Thomas J.
    Yeung, Yik Andy
    Lindquist, Kevin C.
    Chunyk, Allison G.
    Kuang, Bing
    Han, Bora
    Mirsky, Michael
    Pardo, Ingrid
    Buetow, Bernard
    Martin, Thomas G.
    Wolf, Jeffrey L.
    Shelton, David
    Rajpal, Arvind
    Strop, Pavel
    Chaparro-Riggers, Javier
    Sasu, Barbra J.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (11) : 2008 - 2020
  • [27] Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS
    Watts, Justin M.
    Lin, Tara L.
    Mims, Alice S.
    Patel, Prapti
    Shami, Paul J.
    Cull, Elizabeth H.
    Cogle, Christopher R.
    Lee, Cynthia
    Uckun, Fatih
    BLOOD, 2021, 138
  • [28] Treatment of low grade B-cell lymphoma with bispecific CD3XCD19 antibodies and monospecific bivalent CD28 antibodies. Preclinical and clinical data
    Manzke, O
    Tesch, H
    Engert, A
    Diehl, V
    Bohlen, H
    BLOOD, 1996, 88 (10) : 342 - 342
  • [29] Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile
    Li, Keyu
    Yun, Rui
    Chai, Min
    Yakkundi, Poonam
    Rosete, Rodnie
    Li, Gene
    Liu, Liqin
    Ng, Dean
    Hinton, Paul R.
    Kotturi, Maya F.
    Sinclair, Angus M.
    Carroll, Stephen F.
    Muchhal, Umesh
    Keyt, Bruce A.
    BLOOD, 2022, 140 : 6010 - 6011
  • [30] Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+T Cells and CD123+AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
    Godwin, John E.
    Ballesteros-Merino, Carmen
    Lonberg, Nikhil
    Jensen, Shawn
    Moudgil, Tarsem
    Bifulco, Carlo B.
    Wigginton, Jon
    Muth, John
    Davidson-Moncada, Jan K.
    Fox, Bernard
    BLOOD, 2019, 134
12345